HIF-2α-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia

Carcinogenesis

Volumn 31, Issue 7, 2010, Pages 1202-1210

  Wang, Xin ^a   Schneider, Abraham ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OXYGEN; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; SMALL INTERFERING RNA; TYRPHOSTIN; ACTIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; PHOSPHOLIPASE C GAMMA; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CONTROLLED STUDY; FIBROBLAST; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPINDLE CELL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; CELL HYPOXIA; CELL MOTION; HEAD AND NECK TUMOR; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ACTINS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77954370385     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq078     Document Type: Article

References (46)

1. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
2. Gatenby,R.A. et al. (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 4, 891-899.
3. DeBerardinis,R.J. et al. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 7, 11-20.
4. Jemal,A. et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249.
5. Seiwert,T.Y. et al. (2007) The chemoradiation paradigm in head and neck cancer. Nat. Clin. Pract. Oncol., 4, 156-171.
6. Kelley,L.C. et al. (2008) Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer. Clin. Exp. Metastasis, 25, 289-304.
7. Isa,A.Y. et al. (2006) Hypoxia in head and neck cancer. Br. J. Radiol., 79, 791-798.
8. Janssen,H.L. et al. (2005) Hypoxia in head and neck cancer: how much, how important? Head Neck, 27, 622-638.
9. Bacon,A.L. et al. (2004) Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann. Med., 36, 530-539.
10. Aebersold,D.M. et al. (2001) Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61, 2911-2916.
11. Semenza,G.L. (2009) Regulation of cancer cell metabolism by hypoxiainducible factor 1. Semin. Cancer Biol., 19, 12-16.
12. Kaelin,W.G.Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer, 8, 865-873.
13. Mahon,P.C. et al. (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev., 15, 2675-2686.
14. Lando,D. et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev., 16, 1466-1471.
15. Gunaratnam,L. et al. (2003) Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem., 278, 44966-44974.
16. Smith,K. et al. (2005) Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/renal cancer. Cancer Res., 65, 5221-5230.
17. Franovic,A. et al. (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl Acad. Sci. U S A., 104, 13092-13097.
18. Wang,Y. et al. (2009) Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med., 15, 319-324.
19. Franovic,A. et al. (2009) Human cancers converge at the HIF-2alpha oncogenic axis. Proc. Natl Acad. Sci. U S A., 106, 21306-21311.
20. Hynes,N.E. et al. (2009) ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol., 21, 177-184.
21. Harari,P.M. et al. (2009) Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin. Radiat. Oncol., 19, 63-68.
22. Rubin Grandis,J. et al. (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst., 90, 824-832.
23. Temam,S. et al. (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol., 25, 2164-2170.
24. Kumar,B. et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol., 26, 3128-3137.
25. Jeon,G.A. et al. (2004) Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int. J. Cancer, 112, 249-258.
26. Schneider,A. et al. (2008) Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia, 10, 1295-1302.
27. Samanna,V. et al. (2006) Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp. Cell Res., 312, 2214-2230.
28. Sriuranpong,V. et al. (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res., 63, 2948-2956.
29. Morgan,S. et al. (2009) ErbB receptors in the biology and pathology of the aerodigestive tract. Exp. Cell Res., 315, 572-582.
30. Wells,A. et al. (2003) Phospholipase C-gamma1 in tumor progression. Clin. Exp. Metastasis, 20, 285-290.
31. Thomas,S.M. et al. (2003) Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res., 63, 5629-5635.
32. Gupton,S.L. et al. (2007) Filopodia: the fingers that do the walking. Sci. STKE, 400, re5. 1-8.
33. Yamazaki,D. et al. (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci., 96, 379-386.
34. Semenza,G.L. (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 12, 853-859.
35. Onnis,B. et al. (2009) Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med., 13, 2780-2786.
36. Rapisarda,A. et al. (2004) Topoisomerase I-mediated inhibition of hypoxiainducible factor 1: mechanism and therapeutic implications. Cancer Res., 64, 1475-1482.
37. Choi,Y.J. et al. (2009) HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J. Cancer Res. Clin. Oncol., 135, 1047-1053.
38. Baselga,J. et al. (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol., 23, 2445-2459.
39. Rogers,S.J. et al. (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev., 24, 47-69.
40. Dutta,P.R. et al. (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett., 254, 165-177.
41. Koukourakis,M.I. et al. (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol., 24, 727-735.
42. Kondo,K. et al. (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol., 1, E83.
43. Hu,C.J. et al. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol., 23, 9361-9374.
44. Qing,G. et al. (2009) Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr. Opin. Genet. Dev., 19, 60-66.
45. Rapisarda,A. et al. (2004) Schedule-dependent inhibition of hypoxiainducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res., 64, 6845-6848.
46. Rapisarda,A. et al. (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther., 8, 1867-1877.